Deoxyvasicine ketone compound as well as preparation method and anti-inflammatory application thereof

By preparing the deoxydoxydendrone compound ZZMV-17, which competitively antagonizes the CXCR2 receptor and downregulates the NF-κB signaling pathway, the problems of high cytotoxicity and unclear molecular targets ofdendrone compounds in the development of anti-inflammatory drugs were solved, achieving low toxicity and high efficacy in anti-inflammatory effects.

CN122344201APending Publication Date: 2026-07-07GENERAL HOSPITAL OF THE NORTHERN WAR ZONE OF THE CHINESE PEOPLES LIBERATION ARMY
0 Cites 0 Cited by

Patent Information

Application Number
CN202610344271.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-03-20
Publication Date
2026-07-07

AI Technical Summary

Technical Problem

Existing natural products of the alkaloid class have problems such as high cytotoxicity, narrow therapeutic window and unclear molecular targets in the development of anti-inflammatory drugs, making it difficult to obtain new derivatives with stronger activity and lower toxicity.

Method used

By preparing deoxyduckbilline ketone compounds, especially compound ZZMV-17, we were able to competitively antagonize the CXCR2 receptor, downregulate the NF-κB signaling pathway, reduce neutrophil infiltration, and decrease the release of inflammatory factors, thus clarifying its anti-inflammatory mechanism.

Benefits of technology

It achieved significant inhibition of nitric oxide and tumor necrosis factor-α release under low cytotoxic conditions, broadening the therapeutic window and providing stronger anti-inflammatory potential and clinical translation prospects.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention relates to a deoxidized vasicine ketone compound as well as a preparation method and anti-inflammatory application thereof, and belongs to the technical field of medicines. The deoxidized vasicine ketone compound provided by the invention can reduce expression of inflammatory factors in a RAW 264.7 cell inflammation model, and the deoxidized vasicine ketone compound ZZMV-17 achieves an anti-inflammatory effect by antagonizing a CXCR2 receptor and reducing neutrophil infiltration, inflammatory factor cascade release and endothelial injury; in conclusion, the deoxidized vasicine ketone compound reduces neutrophil infiltration and reduces release of inflammatory factors by antagonizing a CXCR2 receptor and regulating downstream signal channels such as NF-kappa B, and has great clinical application value.
Need to check novelty before this filing date? Find Prior Art